Project Oncology®

191 Épisodes

1. Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data

   Publié: 07/01/2025
2. Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols

   Publié: 02/01/2025
3. Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

   Publié: 31/12/2024
4. Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results

   Publié: 23/12/2024
5. Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

   Publié: 23/12/2024
6. Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases

   Publié: 23/12/2024
7. Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01

   Publié: 23/12/2024
8. Understanding Heparin Resistance: Underlying Mechanisms and Alternative Treatment Options

   Publié: 16/12/2024
9. The Future of ITP Care: Exploring New Treatments

   Publié: 16/12/2024
10. Understanding iMCD Through RNA Sequencing

    Publié: 16/12/2024
11. NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker

    Publié: 13/12/2024
12. Diagnosing Castleman Disease: Key Considerations

    Publié: 10/12/2024
13. Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells

    Publié: 09/12/2024
14. Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy

    Publié: 27/11/2024
15. EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC Disease Progression Post ET+CDK4/6i

    Publié: 26/11/2024
16. Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast Cancer

    Publié: 29/10/2024
17. The Long-Term Safety of Momelotinib for Myelofibrosis: A Poster from ASH

    Publié: 29/10/2024
18. Investigating the Impact of Momelotinib on Myelofibrosis Patients: A Poster from ASH

    Publié: 29/10/2024
19. Enhancing Outcomes in Relapsed/Refractory B-ALL with CAR T-Cell Therapy

    Publié: 16/10/2024
20. Momelotinib vs. Ruxolitinib: Comparing Efficacy in Myelofibrosis and Anemia Patients

    Publié: 02/10/2024